Leading Innovation Brands in Active Psoriatic Arthritis Treatment

The Brands Driving Innovation

Several drug brands are consistently recognized by rheumatologists and dermatologists as innovation leaders due to their novel mechanisms, extensive clinical programs, and strong patient outcomes.

These therapies target key inflammatory pathways that drive joint damage and skin disease, enabling more personalized treatment strategies.

BIMZELX Is Setting a New Benchmark

One of the most significant recent innovations is BIMZELX (bimekizumab), developed by UCB.

Unlike earlier IL-17 inhibitors that target only IL-17A, BIMZELX inhibits both IL-17A and IL-17F. Researchers believe these two cytokines work together to drive inflammation, making dual inhibition a promising strategy.

The Phase III BE OPTIMAL trial evaluated more than 850 patients with active PsA. At Week 16, approximately 44% of patients receiving BIMZELX achieved ACR50 compared with around 10% in the placebo group.

The more recent BE BOLD head-to-head study generated considerable attention across the rheumatology community. At Week 16, 49.1% of patients treated with BIMZELX achieved ACR50 compared with 38.4% of patients receiving SKYRIZI. Complete skin clearance (PASI100) was achieved by 53.4% versus 46.6%, respectively.

These results have positioned BIMZELX among the most closely watched biologic innovations in active PsA treatment.

TREMFYA Focuses on Long-Term Joint Protection

TREMFYA (guselkumab) has established itself as a major innovation in the IL-23 inhibitor category.

The DISCOVER-1 and DISCOVER-2 Phase III studies enrolled more than 1,100 patients with active PsA. In these studies, nearly 52% to 64% of patients achieved ACR20 responses at Week 24 compared with approximately 22% to 33% for placebo.

A major milestone came in 2026 when TREMFYA received an FDA label expansion showing evidence of inhibiting structural joint damage progression. This achievement made TREMFYA the first and only IL-23 inhibitor with this specific claim at the time.

For physicians treating patients at risk of irreversible joint destruction, this additional evidence strengthened TREMFYA's position as a leading innovative therapy.

SKYRIZI Continues Rapid Growth

SKYRIZI (risankizumab) has become one of the fastest-growing immunology brands worldwide.

The Phase III KEEPsAKE-1 and KEEPsAKE-2 trials included more than 1,400 patients with active PsA. At Week 24, approximately 57% of patients receiving SKYRIZI achieved ACR20 compared with about 34% receiving placebo.

The therapy has also demonstrated strong skin outcomes. In psoriasis studies, many patients achieved PASI90 and PASI100 responses, helping SKYRIZI gain widespread adoption among both rheumatologists and dermatologists.

AbbVie reported annual SKYRIZI global sales exceeding $13 billion in 2025, making it one of the highest-performing immunology products in the industry.

COSENTYX Remains a Category Pioneer

COSENTYX (secukinumab) was the first IL-17 inhibitor approved for psoriatic arthritis and remains one of the most prescribed biologics globally.

Since its initial approval, more than one million patients across approved indications have been treated with COSENTYX worldwide. Long-term extension studies have demonstrated durable efficacy extending beyond five years in many patients.

Clinical trials showed ACR20 responses ranging from approximately 50% to 60% depending on dose and patient population. The drug also demonstrated significant reductions in enthesitis, dactylitis, and skin symptoms.

Even as newer therapies enter the market, COSENTYX continues to serve as a benchmark against which emerging treatments are measured.

TALTZ Delivers Strong Joint and Skin Responses

TALTZ (ixekizumab) has become another major IL-17 inhibitor in the PsA market.

The SPIRIT clinical development program enrolled more than 1,400 patients across multiple studies. In pivotal trials, nearly 58% to 62% of patients achieved ACR20 responses at Week 24 compared with approximately 30% for placebo.

TALTZ has demonstrated particularly strong performance in patients with significant skin involvement, making it a valuable option for individuals requiring control of both joint and dermatologic symptoms.